Fusariosis: an update on therapeutic options for management

References

• Ams A-H, Meis JF, De Hoog GS. Fusarium: molecular diversity and intrinsic drug resistance. PLoS Pathog. 2016;12(4):e1005464.
   PubMed Web of Science ®Google Scholar
• Ams A-H, Hagen F, Menken SBJ, et al. Global molecular epidemiology and genetic diversity of Fusarium, a significant emerging group of human opportunists from 1958 to 2015. Emerg Microbes Infect. 2016;5(12):e124.
   PubMedGoogle Scholar
• Ams A-H, Bonifaz A, Ranque S, et al.Current antifungal treatment of fusariosis. Int J Antimicrob Agents. 20181; 513: 326–332.10.1016/j.ijantimicag.2017.06.017
   PubMed Web of Science ®Google Scholar
• Phoompoung P, Luong M-L. Treatment of Non-Aspergillus mold infections: a focus on mucormycosis and fusariosis. Curr. Treat. Options Infect. Dis. 2019;11(4):401–417.
   Google Scholar
• O’Donnell K, Rooney AP, Proctor RH, et al. Phylogenetic analyses of RPB1 and RPB2 support a middle Cretaceous origin for a clade comprising all agriculturally and medically important fusaria. Fungal Genet Biol. 2013;52:20–31.
   PubMed Web of Science ®Google Scholar
• Nucci M, Garnica M, Ab G, et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Microbiol Infect. 2013;19(8):745–751.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–1100.
   PubMed Web of Science ®Google Scholar
• Slavin M, Van Hal S, Sorrell TC, et al. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clin Microbiol Infect. 2015;5(5):490.e1-10.
   Google Scholar
• Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20(4):695–704.
   PubMed Web of Science ®Google Scholar
• Ams A-H, Sybren De Hoog G, Jf M. Multiresistant fusarium pathogens on plants and humans: solutions in (from) the antifungal pipeline? Infect Drug Resist. 2019;12:3727–3737.
   PubMed Web of Science ®Google Scholar
• Ams A-H, Bonifaz A, De Hoog GS, et al. Keratitis by Fusarium temperatum, a novel opportunist. BMC Infect Dis. 2014;14:1–9.
   PubMed Web of Science ®Google Scholar
• Short DPG D, O’Donnell K, Zhang N, et al. Widespread occurrence of diverse human pathogenic types of the fungus Fusarium detected in plumbing drains. J Clin Microbiol. 2011;49(12):4264–4272.
   PubMed Web of Science ®Google Scholar
• Guarro J. Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment. Eur J Clin Microbiol Infect Dis. 2013;32(12):1491–1500.
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003;98(2):315–319.
   PubMed Web of Science ®Google Scholar
• Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2004;38(9):1237–1242.
   PubMed Web of Science ®Google Scholar
• Sampathkumar P, Paya CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis. 2001;32(8):1237–1240.
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis. 2002;35(8):909–920.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Ams A-H, Xiang Y, et al. The concept of ecthyma gangrenosum illustrated by a Fusarium oxysporum infection in an immunocompetent individual. Mycopathologia. 2016;181(9–10):759–763.
   Web of Science ®Google Scholar
• Varon AG, Nouer SA, Barreiros G, et al. .Superficial skin lesions positive for Fusarium are associated with subsequent development of invasive fusariosis. J Infect. 2014;68(1):85–89.
   PubMed Web of Science ®Google Scholar
• Dursun D, Fernandez V, Miller D, et al. Advanced Fusarium keratitis progressing to endophthalmitis. Cornea. 2003;22(4):300–303.
   PubMed Web of Science ®Google Scholar
• Ferrer C, Alio J, Rodriguez A, et al. Endophthalmitis caused by Fusarium proliferatum. J Clin Microbiol. 2005;43(10):5372–5375.
   PubMed Web of Science ®Google Scholar
• Ka R, Eliott D, Plous O, et al. Disseminated Fusarium infection presenting as bilateral endogenous endophthalmitis in a patient with acute myeloid leukemia. Arch Ophthalmol. 2005;123(5):702–703.
   PubMedGoogle Scholar
• Tiribelli M, Zaja F, Filì C, et al. Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia. Eur J Haematol. 2002;68(5):314–317.
   PubMed Web of Science ®Google Scholar
• Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect. 2004;10(Suppl. 1):67–75.
   PubMed Web of Science ®Google Scholar
• Boutati EI E, Fusarium AEJ. A significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood. 1997;90(3):999–1008.
   PubMed Web of Science ®Google Scholar
• Tortorano AM, Esposto MC, Prigitano A, et al. Cross-reactivity of Fusarium spp. in the Aspergillus galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol. 2012;50(3):1051–1053.
   PubMed Web of Science ®Google Scholar
• Nucci M, Shoham S, Abdala E, et al. Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis? Mycoses. 2019;26(5):413–417.
   Google Scholar
• Espinel-Ingroff A, Colombo AL, Cordoba S, et al. International evaluation of MIC distributions and epidemiological cutoff value (ECV) definitions for Fusarium species identified by molecular methods for the CLSI broth microdilution method. Antimicrob Agents Chemother. 2016;60(2):1079–1084.
   PubMed Web of Science ®Google Scholar
• Ams A-H, Van Diepeningen AD, Curfs-Breuker I, et al. Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. J Antimicrob Chemother. 2014;70(4):1068–1071.
   PubMed Web of Science ®Google Scholar
• Ams A-H, Curfs-Breuker I, De Hoog GS, et al. Antifungal susceptibility testing of fusarium: a practical approach. J Fungi. 2017;3(2):19.
   Web of Science ®Google Scholar
• Espinel-Ingroff A, Chakrabarti A, Chowdhary A, et al. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. Antimicrob Agents Chemother. 2015;59(3):3.
   Web of Science ®Google Scholar
• Horn DL, Freifeld AG, Schuster MG, et al. Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance ® registry. Mycoses. 2014;57(11):652–658.
   PubMed Web of Science ®Google Scholar
• Nucci M, Marr KA, Vehreschild MJGT, et al. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect. 2014;20(6):580–585.
   PubMed Web of Science ®Google Scholar
• Jr P. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. In: Clin. Infect. Dis. 2005;40:S401–8.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54(10):4446–4450.
   PubMed Web of Science ®Google Scholar
• Np W, Lk N, Bocanegra R, et al. Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. Antimicrob Agents Chemother. 2010;54(3):1055–1059.
   PubMed Web of Science ®Google Scholar
• Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J Infect. 2010;60(5):331–337.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Kessler R, Kravanja C, et al. Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant. 2004;23(12):1451–1454.
   PubMed Web of Science ®Google Scholar
• Ii R, Ry H, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 2006;42(10):1398–1403.
   PubMed Web of Science ®Google Scholar
• Thompson GR, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia. 2010;170(5):291–313.
   PubMed Web of Science ®Google Scholar
• Guinea J, Peláez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008;52(4):1396–1400.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Ostrosky-Zeichner L, Rahav G, et al. Outcomes in patients with invasive mold disease caused by fusarium or scedosporium spp. treated with isavuconazole: experience from the vital and secure trials. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM Washington, DC, USA, 5–9 September 2014. (Abstract no. M-1760).
   Google Scholar
• Al-Hatmi AM, Meletiadis J, Curfs-Breuker I, et al. In vitro combinations of natamycin with voriconazole, itraconazole and micafungin against clinical Fusarium strains causing keratitis: table 1. J Antimicrob Chemother. 2016;71(4):953–955.
   PubMed Web of Science ®Google Scholar
• Tb S, Tp V, Rossato L, et al. Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium. Rev Iberoam Micol. 2013;30(3):200–204.
   PubMed Web of Science ®Google Scholar
• Córdoba S, Rodero L, Vivot W, et al. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents. 2008;31(2):171–174.
   PubMed Web of Science ®Google Scholar
• Liu JY, Chen WT, Ko BS, et al. Combination antifungal therapy for disseminated fusariosis in immunocompromised patients: a case report and literature review. Med Mycol. 2011;49(8):872–878.
   PubMed Web of Science ®Google Scholar
• Jenks JD, Reed SL, Seidel D, et al. Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy. Int J Antimicrob Agents. 2018;52(5):706–712.
   PubMed Web of Science ®Google Scholar
• Stempel JM, Hammond SP, Sutton DA, et al. Invasive fusariosis in the voriconazole era: single-center 13-year experience. Open Forum Infect Dis. 2015;2(3):ofv099.
   PubMed Web of Science ®Google Scholar
• Hassler A, Lieb A, Seidel D, et al. Lehrnbecher, disseminated fusariosis in immunocompromised children - Analysis of recent cases identified in the global fungiscope registry. Pediatr Infect Dis J. 2017;36(2):230–231.
   PubMed Web of Science ®Google Scholar
• Koselny K, Green J, DiDone L, et al. The celecoxib derivative AR-12 has broad-spectrum antifungal activity in vitro and improves the activity of fluconazole in a murine model of cryptococcosis. Antimicrob Agents Chemother. 2016;60(12):7115–7127.
   PubMed Web of Science ®Google Scholar
• Koselny K, Green J, Favazzo L, et al. Antitumor/antifungal celecoxib derivative AR-12 is a non-nucleoside inhibitor of the ANL-family adenylating enzyme acetyl CoA synthetase. ACS Infect Dis. 2016;2(4):268–280.
   PubMed Web of Science ®Google Scholar
• Nakamura I, Yoshimura S, Masaki T, et al. ASP2397: a novel antifungal agent produced by Acremonium persicinum MF-347833, J. Antibiot. (Tokyo). 2017;70(1):45–51.
   PubMed Web of Science ®Google Scholar
• Jd O, Gem S, Beckmann N, et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci U S A. 2016;113(45):12809–12814.
   PubMed Web of Science ®Google Scholar
• McCarthy MW, Kontoyiannis DP, Cornely OA, et al. Novel agents and drug targets to meet the challenges of resistant fungi. J Infect Dis. 2017;216(suppl_3):S474–S483.
   PubMed Web of Science ®Google Scholar
• Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov. 2017;16(9):603–616.
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Horii T, Hata K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother. 2011;55(10):4652–4658.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Fp D, Dj D, et al. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. Antimicrob Agents Chemother. 2012;56(1):352–357.
   PubMed Web of Science ®Google Scholar
• Ma P, Sa M, Mr M, et al. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. By two international methods (CLSI and EUCAST). J. Antimicrob. Chemother 2013;68(4):858–863.
   PubMed Web of Science ®Google Scholar
• Lamoth F, Alexander BD. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. Antimicrob Agents Chemother. 2015;59(7):4308–4311.
   PubMed Web of Science ®Google Scholar
• Pianalto KM, Alspaugh JA. New horizons in antifungal therapy. J Fungi. 2016;2(4):26.
   Web of Science ®Google Scholar
• Ma P, Sa M, Georgopapadakou N, et al. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol. 2009;47(12):3797–3804.
   PubMed Web of Science ®Google Scholar
• Hsu LH, Wang HF, Sun PL, et al. antibiotic polymyxin B exhibits novel antifungal activity against Fusarium species. Int J Antimicrob Agents. 2017Jun;49(6):740–748.
   PubMed Web of Science ®Google Scholar
• Fm L, Dm B, Rh G, et al. Pulmonary resection for fungal infection in children undergoing bone marrow transplantation. J Thorac Cardiovasc Surg. 1992;104(3):684–687.
   PubMed Web of Science ®Google Scholar
• Velasco E, Martins CA, Nucci M. Successful treatment of catheter-related fusarial infection in immunocompromised children. Eur J Clin Microbiol Infect Dis. 1995;14(8):697–699.
   PubMed Web of Science ®Google Scholar
• Roilides E, Farmaki E. Granulocyte colony-stimulating factor and other cytokines in antifungal therapy. Clin Microbiol Infect. 2001;7:62–67.
   PubMed Web of Science ®Google Scholar
• Kadri SS, Remy KE, Strich JR, et al. Role of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience. Transfusion. 2015;55(9):2076–2085.
   PubMed Web of Science ®Google Scholar
• Pa T. Current perspectives on ophthalmic mycoses. Clin Microbiol Rev. 2003;16(4):730–797.
   PubMed Web of Science ®Google Scholar
• Dos Santos CO, Kolwijck E, Van Der Lee HA, et al. In vitro activity of chlorhexidine compared with seven antifungal agents against 98 Fusarium isolates recovered from fungal keratitis patients. Antimicrob Agents Chemother. 2019;63(8):e02669–18.
   PubMed Web of Science ®Google Scholar
• Todokoro D, Suzuki T, Tamura T, et al. Efficacy of luliconazole against broad-range filamentous fungi including Fusarium solani species complex causing fungal keratitis. Cornea. 2019;38(2):238–242.
   PubMed Web of Science ®Google Scholar
• Verrier J, Bontems O, Baudraz-Rosselet F, et al. Oral terbinafine and itraconazole treatments against dermatophytes appear not to favor the establishment of Fusarium spp. in nail. Dermatology. 2014;228(3):225–232.
   PubMed Web of Science ®Google Scholar
• Galletti J, Negri M, Fl G, et al. Fusarium spp. is able to grow and invade healthy human nails as a single source of nutrients. Eur J Clin Microbiol Infect Dis. 2015;34(9):1767–1772.
   PubMed Web of Science ®Google Scholar
• Lurati M, Baudraz-Rosselet F, Vernez M, et al. Efficacious treatment of non-dermatophyte mould onychomycosis with topical amphotericin B. Dermatology. 2012;223(4):289–292.
   Web of Science ®Google Scholar
• Abastabar M, Ams A-H, Moghaddam MV, et al. Potent activities of luliconazole, lanoconazole, and eight comparators against molecularly characterized Fusarium species. Antimicrob Agents Chemother. 2018;62(5):e00009–18.
   PubMed Web of Science ®Google Scholar
• Chen SCA, Playford EG, Sorrell TC. Antifungal therapy in invasive fungal infections. Curr Opin Pharmacol. 2010;10(5):522–530.
   PubMed Web of Science ®Google Scholar
• Tortorano AM, Richardson M, Roilides E, et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect. 2014;20:27–46.
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Salmanton-García J, Walsh TJ, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European confederation of medical mycology in cooperation with the international society for human and animal mycology and the American society for microbiolo. Lancet Infect Dis. 2021;
   PubMed Web of Science ®Google Scholar
• Shoham S, Dominguez EA. Emerging fungal infections in solid organ transplant recipients: guidelines of the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33(9):e13525.
   PubMed Web of Science ®Google Scholar
• Mahfouz T, Miceli MH, Saghafifar F, et al. 18 F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol. 2005;23(31):7857–7863.
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Kuchar RT, Rex JH, et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis. 2001;33(11):1871–1878.
   PubMed Web of Science ®Google Scholar
• Varon AG, Nouér SA, Barreiros G, et al. Antimold prophylaxis may reduce the risk of invasive fusariosis in hematologic patients with superficial skin lesions with positive culture for Fusarium. Antimicrob Agents Chemother. 2016;60(12):7290–7294.
   PubMed Web of Science ®Google Scholar